JW Pharmaceutical Corp (001067) - Total Liabilities
Based on the latest financial reports, JW Pharmaceutical Corp (001067) has total liabilities worth ₩257.46 Billion KRW (≈ $174.47 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore JW Pharmaceutical Corp cash conversion from operations to assess how effectively this company generates cash.
JW Pharmaceutical Corp - Total Liabilities Trend (2014–2024)
This chart illustrates how JW Pharmaceutical Corp's total liabilities have evolved over time, based on quarterly financial data. Check 001067 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
JW Pharmaceutical Corp Competitors by Total Liabilities
The table below lists competitors of JW Pharmaceutical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cell Impact AB
ST:CI
|
Sweden | Skr29.21 Million |
|
Openlearning Ltd
AU:OLL
|
Australia | AU$5.43 Million |
|
Nelson Resources Ltd
AU:NES
|
Australia | AU$327.22K |
|
AHT Syngas Technology NV
F:3SQ1
|
Germany | €6.14 Million |
|
Bergenbio ASA
OL:BGBIO
|
Norway | Nkr19.75 Million |
|
PLAYWITH Inc
KQ:023770
|
Korea | ₩15.75 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down JW Pharmaceutical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see JW Pharmaceutical Corp stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JW Pharmaceutical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JW Pharmaceutical Corp (2014–2024)
The table below shows the annual total liabilities of JW Pharmaceutical Corp from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩275.11 Billion ≈ $186.44 Million |
-27.53% |
| 2023-12-31 | ₩379.60 Billion ≈ $257.25 Million |
-5.62% |
| 2022-12-31 | ₩402.21 Billion ≈ $272.57 Million |
-9.52% |
| 2021-12-31 | ₩444.51 Billion ≈ $301.24 Million |
+30.12% |
| 2020-12-31 | ₩341.62 Billion ≈ $231.51 Million |
-0.44% |
| 2019-12-31 | ₩343.12 Billion ≈ $232.52 Million |
+2.83% |
| 2018-12-31 | ₩333.68 Billion ≈ $226.13 Million |
-7.34% |
| 2017-12-31 | ₩360.10 Billion ≈ $244.03 Million |
-3.91% |
| 2016-12-31 | ₩374.76 Billion ≈ $253.97 Million |
-3.43% |
| 2015-12-31 | ₩388.07 Billion ≈ $262.99 Million |
+5.11% |
| 2014-12-31 | ₩369.22 Billion ≈ $250.21 Million |
-- |
About JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more